# Single-Dose SARS-CoV-2 Vaccination With BNT162b2 and AZD1222 Induce Disparate Th1 Responses and IgA Production

## Supplementary Information

Michael Müller, Johann Volzke, Behnam Subin, Silke Müller, Martina Sombetzki, Emil C. Reisinger, Brigitte Müller-Hilke

#### Contents

Supplementary Figures 1-7

Supplementary Tables 1-3



Supplementary Fig. 1 Vaccination with AZD1222, unlike BNT162b2, led to an intermittent increase in CD14<sup>+</sup>CD16<sup>-</sup>CD11b<sup>+</sup>CD177<sup>-</sup> granulocytes. A Pseudocolor plots for the expression of CD11b and CD177 on SSC<sup>hi</sup>CD14<sup>+</sup>CD16<sup>-</sup> granulocytes are representative for the AZD1222 vaccination group. **B** Proportions of CD177<sup>-</sup>CD11b<sup>+</sup> granulocytes after vaccination with AZD1222 (n = 18, left panel) or BNT162b2 (n = 18, right panel). p-values resulting from Kruskal-Wallis and Dunn's multiple comparisons tests were 0.0004 for AZD1222 and 0.6760 for BNT162b2 analyses, respectively. \*p < 0.05, \*\*p < 0.01



Supplementary Fig. 2 CD14<sup>+</sup>CD16<sup>+</sup>CD11b<sup>-</sup>CD177<sup>-</sup> granulocytes were decreased after vaccination with AZD1222 only. A Pseudocolor plots for the expression of CD11b and CD177 on SSC<sup>hi</sup>CD14<sup>+</sup>CD16<sup>+</sup> granulocytes are representative for the AZD1222 vaccination group. **B** Proportions of CD177<sup>-</sup>CD11b<sup>-</sup> granulocytes after vaccination with AZD1222 (n = 18, left panel) or BNT162b2 (n = 18, right panel). FACS analyses were gated on CD14<sup>+</sup>CD16<sup>+</sup> granulocytes. p-values resulting from Kruskal-Wallis and Dunn's multiple comparisons tests were < 0.0001 for AZD1222 and 0.9152 for BNT162b2 analyses, respectively. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001



Supplementary Fig. 3 AZD1222 vaccination induced the transient increase of CD27<sup>-</sup>CD38<sup>+</sup> terminally differentiated CD8<sup>+</sup> T cells. A Pseudocolor plots for the expression of CD27 and CD38 on CD8<sup>+</sup> T cells are representative for the AZD1222 vaccination group. **B** Proportions of CD8<sup>+</sup>CD27<sup>-</sup>CD38<sup>+</sup> T cells after vaccination with AZD1222 (n = 18, left panel) or BNT162b2 (n = 18, right panel). All FACS analyses were on CD8<sup>+</sup> T cells. p-values resulting from Kruskal-Wallis and Dunn's multiple comparisons tests were 0.0009 for AZD1222 and 0.7905 for BNT162b2 analyses, respectively. \*p < 0.05, \*\*p < 0.01



Supplementary Fig. 4 CD4<sup>+</sup> effector memory T cells re-expressing RA were increased towards the end of the observation period after AZD1222 vaccination. A Pseudocolor plots for the expression of CD127 and CD27 on CD4<sup>+</sup> T cells are representative for the AZD1222 vaccination group. **B** Proportions of CD4<sup>+</sup>CD127<sup>+</sup>CD27<sup>+</sup> T cells after vaccination with AZD1222 (n = 18, left panel) or BNT162b2 (n = 18, right panel). All FACS analyses were on CD4<sup>+</sup> T cells. p-values resulting from one-way ANOVA and Tukey-Kramer multiple comparisons tests were 0.0063 for AZD1222 and 0.4955 for BNT162b2 analyses, respectively. \*p < 0.05, \*\*p < 0.01



Supplementary Fig. 5 Establishment of a protocol for the re-stimulation of SARS-CoV-2 spike protein specific immune cells. PBMCs were isolated from fully vaccinated (n = 6) and COVID-19 convalescent (n = 1) blood donors and were in vitro re-stimulated with either recombinant spike protein (r spike) or the spike protein encoding mRNA (BNT162b2). **A** Representative pseudocolor plots showing the expression of CD137 on CD4<sup>+</sup> (upper panel) or CD8<sup>+</sup> T cells (lower panel) exemplifies activation. **B** Quantitative data for different stimulation regimen show that recombinant spike protein induced the enrichment of activated CD4<sup>+</sup> T cells, whereas spike protein encoding mRNA was able to increase the proportions of both activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells.



#### Supplementary Fig. 6 Gating scheme for the 24-colour immune-phenotyping of

peripheral whole blood cells. Arrows indicate the hierarchical gating steps.



Supplementary Fig. 7 Gating scheme for the intracellular cytokine staining assay, here exemplified for PMA/Ionomycin stimulated PBMC. Expression of the activation markers CD25, CD137 as well as the cytokines IL-2, IL-10, IFN $\gamma$  and TNF $\alpha$  were analyzed on CD4<sup>+</sup> and CD8<sup>+</sup> cells, respectively. IL-4 production was analyzed only on CD4<sup>+</sup> cells while FasL expression was examined for CD8<sup>+</sup> cells only. Arrows indicate the hierarchical gating steps.

	Day 0 (n=18)	Day 2 (n=15)	Day 6 (n=17)	Day 13 (n=16)	Day 20 (n=16)	p-value	
	cells/µL [median]	cells / µL [median]	cells / $\mu$ L [median]	cells / μL [median]	cells / $\mu$ L [median]	(Kruskal-Wallis)	
	(IQR)	(IQR)	(IQR)	(IQR)	(IQR)		
granulocytes	2394	632	2004	2086	2107	< 0.0001	
	(1842-3093)	(479-1101)	(1618-2232)	(1427-2862)	(1355-2850)		
monocytes	369	269	278	252	297	0.3110	
	(253-448)	(226-311)	(252-412)	(189-349)	(174-372)		
lymphocytes	1846	1014	1803	1925	1827	0.0000	
	(1788-2658)	(698-1262)	(1560-2689)	(1585-2687)	(1439-2338)	0.0009	
B cells	216	79	162	246	151	0.0010	
	(140-287)	(57-160)	(126-261)	(187-409)	(122-278)	0.0019	
T cells	1102	560	1114	1178	1005	0.0004	
	(873-1524)	(416-695)	(969-1419)	(893-1416)	(750-1230)		
CD4+ T cells	684	333	734	799	637	0.0026	
	(521-1092)	(262-466)	(596-936)	(584-954)	(494-822)		
CD8+ T cells	325	149	299	291	252	< 0.0001	
	(248-358)	(89-185)	(252-337)	(214-351)	(209-313)		

## Supplementary Table 1 Immune status during early AZD1222 vaccination response

	Day 0 (n=18)	Day 2 (n=17)	Day 6 (n=18)	Day 13 (n=16) Day 20 (n=17)		p-value	
	cells/µL [median]	cells / μL [median]	cells / μL [median]	cells / μL [median]	cells / μL [median]	(Kruskal-Wallis <sup>#</sup> )	
	(IQR)	(IQR)	(IQR)	(IQR)	(IQR)	(one-way ANOVA*)	
granulocytes	1330	1240	1571	1173	1646	0.3834 <sup>#</sup>	
	(1132-2100)	(1043-1683)	(1239-2246)	(831-1836)	(1098-2221)		
monocytes	345	329	303	331	307	0.9404*	
	(215-420)	(251-391)	(253-371)	(257-389)	(216-407)		
lymphocytes	1829	1816	1756	1746	1704	0.770.0*	
	(1332-2076)	(1335-2023)	(1603-2097)	(1441-2674)	(1492-2401)	0.7708*	
B cells	158	147	233	178	229	0.0885*	
	(125-260)	(132-210)	(136-388)	(120-292)	(125-307)		
T cells	945	799	946	986	1046	0.4438 <sup>#</sup>	
	(726-1194)	(705-1104)	(641-1053)	(648-1219)	(761-1409)		
CD4+ T cells	558	511	543	589	623	0.3272#	
	(490-617)	(409-578)	(370-606)	(386-754)	(513-849)		
CD8+ T cells	249	236	241	256	302	0.0400#	
	(183-381)	(167-345)	(197-361)	(196-424)	(230-457)	U.0468 <sup>°</sup>	

## Supplementary Table 2 Immune status during early BNT162b2 vaccination response

## Supplementary Table 3 Responders to vaccines

	IgM [% responders]		IgG [% responders]		IgA [% responders]	
vaccine	AZD1222	BNT162b2	AZD1222	BNT162b2	AZD1222	BNT162b2
day 0	0	0	5.3	0	0	0
day 2	0	0	0	0	0	0
day 6	0	0	11.1	0	0	5.6
day 13	52.9	26.7	47.1	86.7	11.8	100
day 20	52.9	47.1	82.4	100	23.5	100
Fisher's exact test [p value]	0.033		0.55		0.040	